筛选蛋白质结晶条件的试剂盒研发进展

蛋白质结晶条件筛选是蛋白质分子三维结构解析的主要限速环节之一,因此发展筛选效率较高的结晶条件筛选试剂盒有着十分重要的意义.目前广泛应用的结晶条件筛选试剂盒的设计方法主要有不完全因子法、稀疏矩阵法和系统筛选法.结晶学家基于这三种方法研发了一系列用于蛋白质结晶条件筛选的试剂盒.评述了20世纪以来筛选试剂盒的设计方法及应用进展,并展望了其未来的发展方向.     

计算机辅助筛选核酸适配体技术

计算机信息技术已经渗透到我们生活的方方面面,不仅可以辅助药物的筛选,也能够模拟药物的作用.目前已有研究使用计算机辅助技术筛选适配体,对筛选效率的提升和筛选高亲和力的适配体有着重要的指导作用.文中将主要对计算机通过序列评估、结构分析、分子对接3个方面辅助适配体筛选的方法进行综述.     

基于荧光激活细胞分选技术的超高通量酶活性筛选方法及其应用

基于荧光激活细胞分选(FACS)技术的超高通量酶活性筛选方法是新出现的一类高通量筛选技术.它利用流式细胞仪高灵敏度、高通量的特点,能以极高的速度(108/天)对大容量酶基因文库进行筛选.FACS筛选技术的出现突破了常规筛选方法低效、耗时、费力等瓶颈问题,极大地提升了人类对大容量基因文库的探索能力,因此在新酶基因筛选、酶活性检测、酶定向进化等领域有广泛的应用潜力.综述了FACS超高通量酶活性筛选方法的最新研究进展,着重介绍了其在酶定向进化中的应用.     

用氨甲蝶呤偶联琼脂糖亲和吸附法从人肝脏cDNA噬菌体展示文库中筛选氨甲蝶呤相互作用蛋白

目的:利用氨甲蝶呤(MTX)偶联琼脂糖凝胶吸附法从人肝脏细胞cDNA噬菌体展示文库中筛选与MTX相互作用的蛋白.方法:以偶联于琼脂糖凝胶表面的MTX为配基,通过"结合-洗脱-扩增"过程筛选与MTX相互作用的噬菌体.利用PCR对筛选结果进行监测,对筛选得到的噬菌体PCR产物进行序列测定和基因同源性分析.结果:通过五轮亲和筛选富集到特异噬菌体克隆,再通过PCR获得cDNA插入片段.通过BLAST程序搜索GenBank,证明筛选到的片段与人PI-3K相关蛋白激酶SMG-1异构体1蛋白同源性达100%.结论:利用偶联MTX的琼脂糖凝胶作为筛选基质,从T7噬菌体展示cDNA文库中富集特异噬菌体是一种方便、高效的MTX相互作用靶蛋白筛选方法,可为探讨小分子药物的分子作用机制提供借鉴和参考.     

SELEX筛选中不同筛选介质的富集效果比较

目的:比较SELEX筛选中不同筛选介质的富集效果,为高通量筛选奠定基础.方法:以乙肝表面抗原(HBsAg)为靶蛋白,采用两种不同的筛选介质:硝酸纤维素膜和环氧树脂,分别将HBsAg包被其上,利用SELEX技术从随机单链DNA文库中筛选得到富集的亲和配基库,最后通过聚丙烯酰胺凝胶电泳和实时荧光定量PCR检测各自的富集效果.结果:经过16轮筛选,发现实时荧光定量PCR时,硝酸纤维素膜空白管与阳性管的循环阈值均在14循环,无明显区别;而环氧树脂空白管与阳性管的循环阈值区别明显,前者是25循环,后者是18循环.结论:在SELEX筛选中,以环氧树脂为筛选介质更易富集到与靶蛋白特异性结合的核酸适配体.     

新疆双峰驼天然单域抗体库的构建及初步鉴定

旨在构建新疆双峰驼天然单域抗体库,及从中快速筛选VHH抗体.采用两种不同的抗原(溶菌酶和cAb-HEWL23)用天然文库进行筛选,成功筛选到了相应的抗体,并融溶菌酶筛选的VHH抗体(A3-1,A4-1和A10-1)进行表达和初步的ELISA检测.结果显示,A3-1和A10-1具有结合溶菌酶的能力.该方法简单方便、省时省力,可以快速从天然单城抗体库中筛选VHH抗体.     

噬菌体显示技术用于抗体表位的筛选

利用噬菌体随机肽库筛选抗TNF单抗表位的研究中,就抗体的选择、肽库富集的检测、筛选得到的表位多肽的验证及如何提高筛选的成功率等,进行了一些初步探索. 实验结果表明,由识别线性抗原位点的抗体较容易筛选到噬菌体呈现表位,具有较强中和活性的抗体,因多识别空间构型抗原位点而增加筛选难度. NC膜斑点印迹、ELISA及DNA测序均可作为筛选富集的检测方法. 用与天然抗原同源比较的方法及竞争性ELISA分析,可以帮助确定噬菌体呈现多肽是否是抗体表位.     

细胞分子生物学技术在靶向药物筛选中的应用

随着细胞及分子生物学的发展,新技术方法越来越多地用于新靶点建立和药物筛选研究,为药物设计、靶点的选择和用药方案的确定提供理论依据,同时使药物筛选有了更高的特异性,对药物筛选和药理学研究起到了极大的促进作用. 论述了功能基因的筛选、高通量细胞筛选和高内涵筛选技术、反义核酸技术、转基因/基因敲除技术、基因芯片、蛋白质芯片、组织芯片、酶免疫分析、荧光免疫分析、流式细胞技术等方法在靶向药物筛选中的应用.     

噬菌体展示文库筛选技术的研究进展

噬菌体展示技术是将编码外源蛋白或多肽的基因片段定向插入到噬菌体的外壳蛋白基因区,使外源蛋白或多肽通过与噬菌体外壳蛋白融合而表达并展示于噬菌体表面,进而筛选表达特异蛋白或多肽的噬菌体,已发展成为生物学后基因组时代一个强有力的实验技术.噬菌体展示文库的筛选是其关键环节.为了提高筛选效率,许多研究者对传统的筛选技术进行了改进,如选择性感染噬菌体、迟延感染性噬菌体、以DNA为基础的筛选方法、亲合力捕获和反复筛选和封闭筛选法等,用于筛选的靶标也越来越具有多样性,使得这一技术有了更加广阔的发展前景.     

一种安全高效大豆转化筛选体系的建立

以灭草烟作为筛选剂,利用基因枪法建立一种安全高效的大豆遗传转化体系.比较不同筛选剂对大豆胚尖外植体丛生芽诱导数目的影响.与卡那霉素、潮霉素和草胺膦等传统筛选剂相比,以灭草烟作为筛选剂可使丛生芽的数目增加1倍以上.克隆了拟南芥突变体csrl-2中突变的乙酰羟基酸合成酶基因(ahas),以其作为筛选标记基因,构建可利用灭草烟作为筛选剂的植物表达载体.利用基因枪法将该载体转化大豆,获得6棵灭草烟抗性植株,分子检测证明外源ahas基因整合到5棵转基因大豆植株的基因组中.     

An economic view of high compliance as a screening objective.

Accepted wisdom holds that high compliance is essential for a screening programme to be successful. Indeed, a reason that the national breast screening programme is not routinely offered to women aged 65 or more is on the grounds of predicted poor compliance by older women. Increasing compliance is often associated with increased costs. These costs represent a lost opportunity for screening alternative target populations. We question the need for screening programmes to achieve high compliance, and we argue that a screening programme can be efficient with very low levels of compliance. Adopting compliance as a screening objective and as a measure of the success of screening may be detrimental to the efficiency of a screening programme.     

The interdependence between screening methods and screening libraries

The most common methods for discovery of chemical compounds capable of manipulating biological function involves some form of screening. The success of such screens is highly dependent on the chemical materials - commonly referred to as libraries - that are assayed. Classic methods for the design of screening libraries have depended on knowledge of target structure and relevant pharmacophores for target focus, and on simple count-based measures to assess other properties. The recent proliferation of two novel screening paradigms, structure-based screening and high-content screening, prompts a profound rethink about the ideal composition of small-molecule screening libraries. We suggest that currently utilized libraries are not optimal for addressing new targets by high-throughput screening, or complex phenotypes by high-content screening.     

Survival after breast cancer according to participation in organised or opportunistic screening and deprivation

BackgroundMany studies have investigated the survival of women by comparing those who participated in organised screening with those who did not. However, among those who do not participate in organised screening, some women undergo opportunistic screening, but these women remain difficult to identify, particularly in France. Therefore, the aim of this study was to identify opportunistic screening, and then to study survival after breast cancer separately according to participation in organised, opportunistic or no screening, and taking into account sociodemographic inequalities.MethodsThe study population was identified from 3 French cancer registries, whose data was crossed with the screening coordination centers and the National Health Data System to identify the different type of screening. The European Deprivation Index was used to define the level of deprivation. We estimated net survival using the Pohar-Perme method.ResultsThe 5-year net survival probabilities were higher for women who attended organised screening (97.0 %) than for women with opportunistic screening (94.1 %) or non-attenders (78.1 %). According to the level of deprivation, a significant difference was observed between the groups of women screened by organised and opportunistic screening, compared to the non-attenders.ConclusionThe identification of opportunistic screening is an important element in identifying women who do not screening. It enables to us to see that women who do not attend any screening have a much higher loss-of-opportunity in terms of survival than those who participate in organised or opportunistic screening, and even more so in the most deprived areas.     

CHALLENGING THE RHETORIC OF CHOICE IN PRENATAL SCREENING

Prenatal screening, consisting of maternal serum screening and nuchal translucency screening, is on the verge of expansion, both by being offered to more pregnant women and by screening for more conditions. The Society of Obstetricians and Gynaecologists of Canada and the American College of Obstetricians and Gynecologists have each recently recommended that screening be extended to all pregnant women regardless of age, disease history, or risk status. This screening is commonly justified by appeal to the value of autonomy, or women's choice. In this paper, I critically examine the value of autonomy in the context of prenatal screening to determine whether it justifies the routine offer of screening and the expansion of screening services. I argue that in the vast majority of cases the option of prenatal screening does not promote or protect women's autonomy. Both a narrow conception of choice as informed consent and a broad conception of choice as relational reveal difficulties in achieving adequate standards of free informed choice. While there are reasons to worry that women's autonomy is not being protected or promoted within the limited scope of current practice, we should hesitate before normalizing it as part of standard prenatal care for all.     

Group screening for rare events based on incomplete block designs

Fields such as, diagnostic testing, biotherapeutics, drug development, and toxicology among others, center on the premise of searching through many specimens for a rare event. Scientists in the business of “searching for a needle in a haystack” may greatly benefit from the use of group screening design strategies. Group screening, where specimens are composited into pools with each pool being tested for the presence of the event, can be much more cost-efficient than testing each individual specimen. A number of group screening designs have been proposed in the literature. Incomplete block screening designs are described here and compared with other group screening designs. It is shown under certain conditions, that incomplete block screening designs can provide nearly a 90% cost saving compared to other group screening designs such as when prevalence is 0.001 and screening 3876 specimens with an ICB-sequential design vs. a Dorfman design. In other cases, previous group screening designs are shown to be most efficient. Overall, when prevalence is small (≤0.05) group screening designs are shown to be quite cost effective at screening a large number of specimens and in general there is no one design that is best in all situations. © 2018 American Institute of Chemical Engineers Biotechnol Progress, 35: e2770, 2019.     

Screening for congenital dislocation of the hip: an economic appraisal.

The direct costs of screening for congenital dislocation of the hip (CDH) are compared with the treatment costs resulting from no screening in a cost-effectiveness analysis in British Columbia. Under certain conditions the costs associated with screening and subsequent conservative treatment for 6 to 15 positive cases of CDH/1000 liveborn infants were considerably lower than the costs of either open or closed reduction of the hip for 1.5 infants with CDH per 1000 infants not screened. When adjustments were made to the assumptions about screening costs, rates with which cases were missed and hospital treatment costs, only the assumptions thought to be overly unfavourable to screening and overly optimistic for no screening brought the costs of no screening within the likely range of costs of screening. Some specific and general implications of the cost-effectiveness of screening for CDH in British Columbia are discussed.     

Cost-Effectiveness Analysis of Risk-Factor Guided and Birth-Cohort Screening for Chronic Hepatitis C Infection in the United States

Background

No consensus exists on screening to detect the estimated 2 million Americans unaware of their chronic hepatitis C infections. Advisory groups differ, recommending birth-cohort screening for baby boomers, screening only high-risk individuals, or no screening. We assessed one-time risk assessment and screening to identify previously undiagnosed 40–74 year-olds given newly available hepatitis C treatments.

Methods and Findings

A Markov model evaluated alternative risk-factor guided and birth-cohort screening and treatment strategies. Risk factors included drug use history, blood transfusion before 1992, and multiple sexual partners. Analyses of the National Health and Nutrition Examination Survey provided sex-, race-, age-, and risk-factor-specific hepatitis C prevalence and mortality rates. Nine strategies combined screening (no screening, risk-factor guided screening, or birth-cohort screening) and treatment (standard therapy–peginterferon alfa and ribavirin, Interleukin-28B-guided (IL28B) triple-therapy–standard therapy plus a protease inhibitor, or universal triple therapy). Response-guided treatment depended on HCV genotype. Outcomes include discounted lifetime costs (2010 dollars) and quality adjusted life-years (QALYs).Compared to no screening, risk-factor guided and birth-cohort screening for 50 year-olds gained 0.7 to 3.5 quality adjusted life-days and cost $168 to $568 per person. Birth-cohort screening provided more benefit per dollar than risk-factor guided screening and cost $65,749 per QALY if followed by universal triple therapy compared to screening followed by IL28B-guided triple therapy. If only 10% of screen-detected, eligible patients initiate treatment at each opportunity, birth-cohort screening with universal triple therapy costs $241,100 per QALY. Assuming treatment with triple therapy, screening all individuals aged 40–64 years costs less than $100,000 per QALY.

Conclusions

The cost-effectiveness of one-time birth-cohort hepatitis C screening for 40–64 year olds is comparable to other screening programs, provided that the healthcare system has sufficient capacity to deliver prompt treatment and appropriate follow-on care to many newly screen-detected individuals.     

Statistical Assessment of Jointly Observed Screening Tests

In this article, Lindley and Novick criteria of screening usefulness is applied to the statistical assessment of jointly observed screening test. Posterior probabilities comparing screening sensitivities and specificities, and posterior probability bounds to comparing screening predictive values are obtained.     

Trends in socioeconomic inequalities in cervical,breast, and colorectal cancer screening participation among women in Japan, 2010–2019

BackgroundIt is known that socioeconomic status (SES) influences the outcome of cancer treatment and this could partly be explained by decreased use of cancer screening services by people of lower SES. Many studies have indicated that low SES, including low educational attainment or unstable employment, was related to nonparticipation in cancer screening. However, studies investigating trends in SES inequalities within cancer screening participation are limited. Our objective was to examine trends in SES inequalities in cervical, breast, and colorectal cancer screening participation among women in Japan between 2010 and 2019.MethodsWe analyzed 189,442, 168,571, 163,341, and 150,828 women in 2010, 2013, 2016, and 2019 respectively, using nationally representative cross-sectional surveys. The main outcome variables are participation in each cancer screening. We used educational attainment and employment status as measures for SES. Multivariable logistic regression analysis, adjusted for age, marital status, educational attainment, and employment status was performed to evaluate the associations between SES and nonparticipation in each cancer screening.ResultsOverall participation rates in each cancer screening increased between 2010 and 2019. Low educational attainment and non-permanent employment status were related to nonparticipation in each cancer screening and inequality according to employment status increased within each screening participation during the study period. For example, dispatched workers were more likely to not participate in cervical cancer screening than permanent workers: in 2010, [aOR 1.11 95 %CI: 1.01 –1.21], and in 2019, [aOR 1.46 95 %CI: 1.34–1.60]. The inequality was greatest in colorectal cancer screening nonparticipation, followed by breast and cervical screening.ConclusionsAlthough the participation rates in each cancer screening have increased, inequality in participation in terms of employment status widened among women in Japan between 2010 and 2019. Reducing inequalities in cancer screening participation is essential for cancer screening intervention policies.     

噬菌体抗体库筛选技术研究进展

噬菌体抗体库技术是一项新兴的基因工程抗体技术,应用这项技术获得高特异性抗体的关键之一就是筛选环节。根据抗原性质以及筛选目的的不同,筛选方法的选择也不相同,各种筛选策略的优化对中和抗体的获得有至关重要的作用。